antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-9-10-25-34antibiotics-965Research ArticleЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИExperimental ResearchСинергетическая комбинация амфотерицина В и антисептика мирамистина может быть эффективной в борьбе с лекарственно-устойчивыми изолятами грибов рода CandidaSynergistic Combination of Amphotericin B and Antiseptic Miramistin May Be Effective in the Fight Against Drug-Resistant Isolates of Candida FungiКирсановаМ. А.КirsanovaM. A.

Кирсанова Марина Александровна — к. б. н., доцент кафедры микробиологии, вирусологии и иммунологии Медицинской академии им. С. И. Георгиевского 

бул. Ленина, 5/7, г. Симферополь, 295051

Marina A. Кirsanova — Ph. D. in Biology, Associate Professor at the Department of Microbiology, Virology, and Immunology 

5/7. Lenina blvd, Simferopol, Republic of Crimea, 295007 

m.a_kirsanova@mail.ruhttps://orcid.org/0000-0003-1380-983XКриворутченкоЮ. Л.KrivorutchenkoYu. L.

Kриворутченко Юрий Леонидович — д. м. н., профессор, заведующий кафедрой микробиологии, вирусологии и иммунологии

Симферополь 

Yuri L. Krivorutchenko — D. Sc. in Medicine, Professor, Head of the Department of Microbiology, Virology, and Immunology 

Simferopol

https://orcid.org/0000-0003-2113-4107ПостниковаО. Н.PostnikovaO. N.

Постникова Ольга Николаевна — старший преподаватель кафедры микробиологии, вирусологии и иммунологии

Симферополь 

Olga N. Postnikova — Senior Lecturer of the Department of Microbiology, Virology, and Immunology 

Simferopol

https://orcid.org/0000-0001-9053-1785АндроновскаяИ. Б.AndronovskajaI. B.

Андроновская Ирина Борисовна — к. б. н., доцент; доцент кафедры микробиологии, вирусологии и иммунологии

Симферополь 

Irina B. Andronovskaja — Ph. D. in Biology, Associate Professor; Associate Professor of the Department of Microbiology, Virology, and Immunology 

Simferopol

Крымский федеральный университет им. В. И. Вернадского, Медицинская академия им. С. И. ГеоргиевскогоРоссияV. I. Vernadsky Crimean Federal University, Medical Academy named after S. I. GeorgievskyRussian Federation202228122022679-102534Copyright © Кирсанова М.А., Криворутченко Ю.Л., Постникова О.Н., Андроновская И.Б., 20222022Кирсанова М.А., Криворутченко Ю.Л., Постникова О.Н., Андроновская И.Б.Кirsanova M.A., Krivorutchenko Y.L., Postnikova O.N., Andronovskaja I.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/965

Создание синергетических комбинаций противогрибковых и антисептических средств можно рассматривать как одну из перспективных стратегий снижения распространения лекарственной устойчивости у патогенных грибов.Цель. Изучение синергетической антифунгальной активности амфотерицина В (AMB) и антисептика мирамистина (МСТ) при их комбинированном применении для борьбы с грибами рода Сandida, устойчивыми к лекарственным препаратам.Материал и методы. Исследовали устойчивый к АМВ штамм C.albicans (минимальная подавляющая концентрация (МПК) 3,1 мкг/мл), чувствительный к МСТ, два изолята C.albicans с различной устойчивостью к MСT и АМВ (МПК 1,6–6,3 мкг/мл) и один MСT-устойчивый изолят C.lusitaniae, чувствительный к АМВ (МПК 0,4 мкг/мл). Чувствительность изолятов к АМВ и MСT по отдельности определяли с помощью метода микроразведений в бульоне и количественного суспензионного метода определения скорости инактивации грибов, соответственно. Индивидуальную противокандидозную активность препаратов сравнивали с активностью комбинаций 0,001% МСТ с АМВ в концентрациях 10 или 50 мкг/мл с помощью определения скорости инактивации грибов.Результаты. Значительное снижение роста всех изолятов, обработанных обеими комбинациями МСТ и АМВ, по сравнению с обработкой отдельными препаратами, наблюдалось в каждом изученном временном интервале (15–60 мин). В составе комбинации МСТ проявлял значительный синергизм с АМВ в сублетальной концентрации 10 мкг/мл, действуя против всех изолятов. Обработка грибов комбинацией МСТ с АМВ в концентрации 50 мкг/мл вызывала полную инактивацию всех изолятов после 30-минутной инкубации. В этих условиях АМВ проявлял антифунгальную активность, действуя отдельно.Заключение. Полученные результаты предполагают возможное эффективное использование мирамистина в комбинации с амфотерицином В против изолятов грибов рода Candida, имеющих множественную лекарственную устойчивость.

Creation of synergistic combinations of antifungal and antiseptic agents can be considered as one of the promising strategies for reducing the spread of drug resistance in pathogenic fungi.Aim. The aim of this work was to study the synergistic antifungal activity of amphotericin B (AMB) and antiseptic miramistin (MST) in their combined use to fight against drug-resistant Candida isolates. Material and methods. One AMB-resistant C.albicans strain (MIC 3.1 µg/ml), sensitive to MST, two isolates of C.albicans with different level of resistance to MST and AMB (MIC 1.6–6.3 µg/ml), and one MST-resistant C.lusitaniae isolate susceptible to AMB (MIC 0.4 µg/ml) were studied. Isolates’ susceptibility to AMB and MST alone was determined by broth microdilution method and time–kill assay, respectively. Individual anti-candida activity of test combinations of 0.001% MST with AMB in 10 or 50 µg/ml concentrations was studied using quantitative time–kill assay.Results. A significant decrease in the growth of all the isolates treated with both test combinations of MST and AMB in comparison with individual medication treatment was observed at each time interval studied (15–60 minutes). As part of the combination, MST exhibited significant synergy with AMB in sublethal concentration of 10 µg/ml against all the isolates. Treatment of the fungi with a combination of MST with AMB in 50 µg/ml concentration caused complete inactivation of all the isolates after 30 minutes. Under these conditions, AMB exhibited separate antifungal activity.Conclusion. These findings suggest the possible effective use of miramistin in combination with amphotericin B against multi-drug resistant isolates of the genus Candida.

Candida spp.лекарственная устойчивостьантисептикмирамистинсинергияамфотерицин ВCandida spp.drug resistanceantiseptic miramistinsynergyamphotericin BReferencesАхапкина И.Г., Глушакова А.М., Родионова Е.Н., Качалкин А.В. Эффективность антифунгальных препаратов в отношении грибов рода Сandida, выделенных в Московском регионе. Антибиотики и химиотер. 2020; 65 (3–4): 16–22. https://doi.org/10.37489/0235-2990-2020-65-3-4-16-22. [Akhapkina I.G., Glushakova A.M., Rodionova E.N., Kachalkin A.V. The Effectiveness of antifungal agents against yeasts of Сandida genus isolated in Moscow Region. Antibiotiki i khimioter = Antibiotics and Chemotherapy. 2020; 65 (3–4): 16–22. https://doi.org/10.37489/0235-2990-2020-65-3-4-16-22. [in Russian]Ахапкина И.Г., Глушакова А.М., Родионова Е.Н., Качалкин А.В. Эффективность антифунгальных препаратов в отношении грибов рода Сandida, выделенных в Московском регионе. Антибиотики и химиотер. 2020; 65 (3–4): 16–22. https://doi.org/10.37489/0235-2990-2020-65-3-4-16-22. [Akhapkina I.G., Glushakova A.M., Rodionova E.N., Kachalkin A.V. The Effectiveness of antifungal agents against yeasts of Сandida genus isolated in Moscow Region. Antibiotiki i khimioter = Antibiotics and Chemotherapy. 2020; 65 (3–4): 16–22. https://doi.org/10.37489/0235-2990-2020-65-3-4-16-22. [in Russian]Osmanov A., Wise A., Denning D.W. In vitro and in vivo efficacy of miramistin against drug-resistant fungi. J. Med. Microbiol. 2019; 68 (7): 1047–1052. doi: 10.1099//jmm.0.001007.Osmanov A., Wise A., Denning D.W. In vitro and in vivo efficacy of miramistin against drug-resistant fungi. J. Med. Microbiol. 2019; 68 (7): 1047–1052. doi: 10.1099//jmm.0.001007.Farmakiotis D., Kontoyiannis D.P. Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management. Int J Antimicrob Agents. 2017; 50: 318–324. doi: 10.1016/j.ijantimicag.2017.05.019.Farmakiotis D., Kontoyiannis D.P. Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management. Int J Antimicrob Agents. 2017; 50: 318–324. doi: 10.1016/j.ijantimicag.2017.05.019.Van Dijck P., Sjollema J., Cammue B.P.A., Lagrou K., Berman J., d`Enfert C. et al. Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell. 2018; 5 (7): 300–326. doi: 10.15698/mic2018.07.638.Van Dijck P., Sjollema J., Cammue B.P.A., Lagrou K., Berman J., d`Enfert C. et al. Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell. 2018; 5 (7): 300–326. doi: 10.15698/mic2018.07.638.Thevissen K. How promising are combinatorial drug strategies in combating Candida albicans biofilms? Future Med Chem. 2016; 8: 1383–1385. doi: 10.4155/fmc-2016-0127.Thevissen K. How promising are combinatorial drug strategies in combating Candida albicans biofilms? Future Med Chem. 2016; 8: 1383–1385. doi: 10.4155/fmc-2016-0127.Hill J.A., Cowen L.E. Using combination therapy to thwart drug resistance. Future Microbiol. 2015; 10 (11): 1719–26. doi: 10.2217/fmb.15.68Hill J.A., Cowen L.E. Using combination therapy to thwart drug resistance. Future Microbiol. 2015; 10 (11): 1719–26. doi: 10.2217/fmb.15.68Jezikova Z., Pagac T., Viglas J., Pfeiferova B., Soltys K., Bujdakova H., et al. Synergy over monotherapy. Curr Microbiol. 2019; 76 (6): 673–677. doi: 10.1007/s00284-019-01678-9.Jezikova Z., Pagac T., Viglas J., Pfeiferova B., Soltys K., Bujdakova H., et al. Synergy over monotherapy. Curr Microbiol. 2019; 76 (6): 673–677. doi: 10.1007/s00284-019-01678-9.Gao M., Wang H., Zhu L. Quercetin assists fluconazole to inhibit biofilm formations of fluconazole-resistant Candida albicans in in vitro and in vivo antifungal managements of vulvovaginal candidiasis. Cell Physiol Biochem. 2016; 40 (3–4): 727–724. doi: 10.1159/000453134.Gao M., Wang H., Zhu L. Quercetin assists fluconazole to inhibit biofilm formations of fluconazole-resistant Candida albicans in in vitro and in vivo antifungal managements of vulvovaginal candidiasis. Cell Physiol Biochem. 2016; 40 (3–4): 727–724. doi: 10.1159/000453134.Fathilah A.R., Himratul-Aznita W.H., Fatheen A.R.N., Suriani K.R. The antifungal properties of chlorhexidine digluconate and cetylpyrinidinium chloride on oral Candida. J Dent. 2012; 40 (7): 609–615. doi: 10.1016/j.jdent.2012.04.003.Fathilah A.R., Himratul-Aznita W.H., Fatheen A.R.N., Suriani K.R. The antifungal properties of chlorhexidine digluconate and cetylpyrinidinium chloride on oral Candida. J Dent. 2012; 40 (7): 609–615. doi: 10.1016/j.jdent.2012.04.003.Reginato C.F., Bandeira L.A., Zanette R.A., Santurio J.M., Alves S.H., Danesi C.C. Antifungal activity of synthetic antiseptics and natural compounds against Candida dubliniensis before and after in vitro fluconazole exposure. Rev Soc Bras Med Trop. 2017; 50 (1): 75–79. doi: 10.1590/0037-8682-0461-2016.Reginato C.F., Bandeira L.A., Zanette R.A., Santurio J.M., Alves S.H., Danesi C.C. Antifungal activity of synthetic antiseptics and natural compounds against Candida dubliniensis before and after in vitro fluconazole exposure. Rev Soc Bras Med Trop. 2017; 50 (1): 75–79. doi: 10.1590/0037-8682-0461-2016.Scheibler E., da Silva R.M., Leite C.E., Campos M.M., Figueiredo M.A., Salum F.G. et al. Stability and efficacy of combined nystatin and chlorhexidine against suspensions and biofilms of Candida albicans. Arch Oral Biol. 2018; 89: 70–76. doi: 10.1016/j.archoralbio.2018.02.009.Scheibler E., da Silva R.M., Leite C.E., Campos M.M., Figueiredo M.A., Salum F.G. et al. Stability and efficacy of combined nystatin and chlorhexidine against suspensions and biofilms of Candida albicans. Arch Oral Biol. 2018; 89: 70–76. doi: 10.1016/j.archoralbio.2018.02.009.Chandra S.S., Miglani R., Srinivasan M.R., Indira R. Antifungal efficacy of 5.25% sodium hypochlorite, 2% chlorhexidine gluconate, and 17% EDTA with and without an antifungal agent. J Endod. 2010; 36 (4): 675–678. doi: 10.1016/j.joen.2010.01.015.Chandra S.S., Miglani R., Srinivasan M.R., Indira R. Antifungal efficacy of 5.25% sodium hypochlorite, 2% chlorhexidine gluconate, and 17% EDTA with and without an antifungal agent. J Endod. 2010; 36 (4): 675–678. doi: 10.1016/j.joen.2010.01.015.Agafonova M.N., Kazakova R.R., Lubina A.P., Zeldi M.I., Nikitina E.V., Balakin K.V. et al. Antibacteruial activity profile of miramistin in in vitro and in vivo models. Microb Pathog. 2020; 142: 104072. doi: 10.1016/j.micpath.2020.104072.Agafonova M.N., Kazakova R.R., Lubina A.P., Zeldi M.I., Nikitina E.V., Balakin K.V. et al. Antibacteruial activity profile of miramistin in in vitro and in vivo models. Microb Pathog. 2020; 142: 104072. doi: 10.1016/j.micpath.2020.104072.Fromm-Dornieden C., Rembe J.D., Schafer N., Bohm J., Stuermer E.K. Cetylpyridinium chloride and miramistin as antiseptic substances in chronic wound management — prospects and limitations. J Med Microbiol. 2015; 64 (Pt 4): 407–414. doi: 10.1099/jmm.0/000034.Fromm-Dornieden C., Rembe J.D., Schafer N., Bohm J., Stuermer E.K. Cetylpyridinium chloride and miramistin as antiseptic substances in chronic wound management — prospects and limitations. J Med Microbiol. 2015; 64 (Pt 4): 407–414. doi: 10.1099/jmm.0/000034.Hatipoglu N., Hatipoglu H. Combination antifungal therapy for invasive fungal infections in children and adults. Expert Rev. Anti Infect. Ther. 2013; 11 (5): 523–535. doi: 10.1586/eri.13.29.Hatipoglu N., Hatipoglu H. Combination antifungal therapy for invasive fungal infections in children and adults. Expert Rev. Anti Infect. Ther. 2013; 11 (5): 523–535. doi: 10.1586/eri.13.29.Baddley J.M., Poppas P.G. Antifungal combination therapy. Drugs 2005; 65: 1461–1480. doi: 10.2165/00003495-200565110-00002.Baddley J.M., Poppas P.G. Antifungal combination therapy. Drugs 2005; 65: 1461–1480. doi: 10.2165/00003495-200565110-00002.Felipe L.O., Junior W.F.D.S., Araujo K.C., Fabrino D.L. Lactoferrin, chitosan and Melaleuca alternifolia–natural products that show promise in candidiasis treatment. Braz.J.Microbiol. 2018; 49 (2): 212–219. doi: 10.1016/j.bjm.2017.05.008.Felipe L.O., Junior W.F.D.S., Araujo K.C., Fabrino D.L. Lactoferrin, chitosan and Melaleuca alternifolia–natural products that show promise in candidiasis treatment. Braz.J.Microbiol. 2018; 49 (2): 212–219. doi: 10.1016/j.bjm.2017.05.008.Zhou Y., Wang G., Li Y., Liu Y., Song Y., Zheng W. et al. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C.parapsilosis. Antimicrob Agents Chemother. 2012; 56 (6): 3250–3260. doi: 10.1128/AAC.06082-11.Zhou Y., Wang G., Li Y., Liu Y., Song Y., Zheng W. et al. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C.parapsilosis. Antimicrob Agents Chemother. 2012; 56 (6): 3250–3260. doi: 10.1128/AAC.06082-11.You J.L., Du L., King J.B., Hall B.E., Cichewicz R.H. Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates. ACS Chem Biol. 2013; 8 (4): 840–848. doi: 10.1021/cb400009f.You J.L., Du L., King J.B., Hall B.E., Cichewicz R.H. Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates. ACS Chem Biol. 2013; 8 (4): 840–848. doi: 10.1021/cb400009f.Khan M.S.A., Malik A., Ahmad I. Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans. Med Mycol. 2012; 50 (1): 33–34. doi: 10.3109/13693786.2011.582890.Khan M.S.A., Malik A., Ahmad I. Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans. Med Mycol. 2012; 50 (1): 33–34. doi: 10.3109/13693786.2011.582890.Di Vito M., Mattarelli P., Modesto M., Girolamo A., Ballardini M., Tamburro A. et al. In vitro activity of tea tree oil vaginal suppositories against Candida spp. and probiotic vaginal microbiota. Phytother Res. 2015; 29 (10): 1628–1633. doi: 10.1002/ptr.5422.Di Vito M., Mattarelli P., Modesto M., Girolamo A., Ballardini M., Tamburro A. et al. In vitro activity of tea tree oil vaginal suppositories against Candida spp. and probiotic vaginal microbiota. Phytother Res. 2015; 29 (10): 1628–1633. doi: 10.1002/ptr.5422.Venkatesh M., Rong L., Raad I., Versalovic J. Novel synergistic antibiofilm combinations for salvage of infected catheters. J Med Microbiol. 2009; 58: 936–944. doi: 10.1099/jmm.0.009761-0.Venkatesh M., Rong L., Raad I., Versalovic J. Novel synergistic antibiofilm combinations for salvage of infected catheters. J Med Microbiol. 2009; 58: 936–944. doi: 10.1099/jmm.0.009761-0.Oliveira dos Santos C., Kalwijck E., van der Lee H.A., Tehupeiory-Kooreman M.C., Al-Hatmi A.M.S., Matayan E. et al. In vitro activity of chlorhexidine compared with seven antifungal agents against 98 Fusarium isolates recovered from fungal keratitis patients. Antimicrob Agents Chemother. 2019; 63 (8): e02669–18. doi: 10.1128/AAC.02669-18.Oliveira dos Santos C., Kalwijck E., van der Lee H.A., Tehupeiory-Kooreman M.C., Al-Hatmi A.M.S., Matayan E. et al. In vitro activity of chlorhexidine compared with seven antifungal agents against 98 Fusarium isolates recovered from fungal keratitis patients. Antimicrob Agents Chemother. 2019; 63 (8): e02669–18. doi: 10.1128/AAC.02669-18.Brady A., Loughlin R., Gilpin D., Kearney P., Tunney M. In vitro activity of tea-tree oil against clinical skin isolates of meticillin-resistant and — sensitive Staphylococcus aureus and coagulase-negative staphylococci growing planktonically and as biofilms. J Med Microbiol. 2006; 55 (Pt 10): 1375–1380. doi: 10.1099/jmm.0.46558-0.Brady A., Loughlin R., Gilpin D., Kearney P., Tunney M. In vitro activity of tea-tree oil against clinical skin isolates of meticillin-resistant and — sensitive Staphylococcus aureus and coagulase-negative staphylococci growing planktonically and as biofilms. J Med Microbiol. 2006; 55 (Pt 10): 1375–1380. doi: 10.1099/jmm.0.46558-0.Pfaller M.A., Bale M., Buschelman B., Lancaster M., Espinel-Ingroff A., Rex J.H. et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995; 33 (5): 1104–1107. doi: 10.1128/JCM.33.5.1104-1107.1995.Pfaller M.A., Bale M., Buschelman B., Lancaster M., Espinel-Ingroff A., Rex J.H. et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995; 33 (5): 1104–1107. doi: 10.1128/JCM.33.5.1104-1107.1995.Cui J., Ren B., Tong Y., Dai H., Zhang L. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans. Virulence 2015; 6(4): 362-371. doi: 10.1080/21505594.2015.1039885Cui J., Ren B., Tong Y., Dai H., Zhang L. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans. Virulence 2015; 6(4): 362-371. doi: 10.1080/21505594.2015.1039885Yang Y.L., Li S.Y., Cheng H.H., Lo H.J. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan. BMC Infect Dis. 2005; 5: 99–103. doi: 10.1186/1471-2334-5-99.Yang Y.L., Li S.Y., Cheng H.H., Lo H.J. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan. BMC Infect Dis. 2005; 5: 99–103. doi: 10.1186/1471-2334-5-99.

The authors declare that there are no conflicts of interest present.